Abstract: The present invention relates to a polypeptide comprising 7 ?-strands A, B, C, D, E, F, and G sequentially connected together by connecting chains of amino acids, and a first ?-helix sequentially located on the EF chain between ?-strands E and F, wherein the ?-strands are arranged so as to form a first ?-sheet comprising ?-strands A, B, D, and E, and a second ?-sheet comprising ?-strands C, F and G, said first and second ?-sheets being covalently bonded together so as to form a first Ig domain; wherein the EF chain between ?-strands E and F comprises the sequence X1-X2-X3-X4-K5H6 (SEQ ID NO:98), and X1, X3 and X4 are each independently any amino acid residue, characterized in that X2 is selected from the group consisting of A, G, I, V, L, R, S, T, Q, P, N, M, H, W, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereof.

Abstract: A system for detecting an infectious agent. The system has a microfluidic apparatus having a first port for receiving a sample and a second port; an electrochemical sensing structure for engaging the microfluidic apparatus and in fluid communication therewith for receiving the sample therefrom; and a bio-sensing apparatus having one or more circuitries for electrically coupling to the electrochemical sensing structure for detecting the infectious agent/analytes from the samples received thereon.

Abstract: A data storage interface provides access to data storage clusters that may not otherwise be accessible to data accessors. The data storage interface can serve as a point of access for data accessors to access stored data via a consistent data access protocol, even when a data storage cluster on which requested data is stored may use a different protocol. The data storage interface can also provide access across network boundaries, such as those between different private cloud computing systems (e.g., virtual private clouds or “VPCs”).

Abstract: The present disclosure provides GIP receptor agonist peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of diabetes, obesity, emesis, or a symptom or condition associated with diabetes, obesity, or emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are provided. Formula I: P1-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A341-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-P2 (SEQ ID NO: 4), or a salt thereof, wherein each symbol is as defined herein, with the proviso that the GIP receptor agonist peptide does not have an amino acid sequence as provided in SEQ ID NOs: 4-569 disclosed in PCT/JP2018/013540.

Abstract: The present disclosure provides GIF receptor agonist peptide compounds having an activating action on GIF receptors and use of the GIF receptor agonist peptide as a medicament for the treatment and/or prevention of emesis. Specifically, a GIF receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are N provided. Formula (I) P1-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-A42-P2, wherein each symbol is as defined herein, with the proviso that the GIF receptor agonist peptide is not native human GIF having an amino acid sequence as set forth in SEQ ID NO: 1.

Abstract: The present invention relates to a polypeptide comprising 7 ?-strands A, B, C, D, E, F, and G sequentially connected together by connecting chains of amino acids, and a first ?-helix sequentially located on the EF chain between ?-strands E and F, wherein the ?-strands are arranged so as to form a first ?-sheet comprising ?-strands A, B, D, and E, and a second ?-sheet comprising ?-strands C, F and G, said first and second ?-sheets being covalently bonded together so as to form a first Ig domain; wherein the EF chain between ?-strands E and F comprises the sequence X1-X2-X3-X4-K5H6 (SEQ ID NO:98), and X1, X3 and X4 are each independently any amino acid residue, characterized in that X2 is selected from the group consisting of A, G, I, V, L, R, S, T, Q, P, N, M, H, W, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereof

Abstract: Techniques for providing an on-demand development environment are described. A service of a provider network receives a request to launch a development environment, such as a notebook, from an electronic device. The service obtains an identification of a computing cluster hosted by the provider network. The service obtains an identification of a compute instance hosted within the provider network, the compute instance executing a software environment to host one or more development environments. The service causes the compute instance to launch a development environment. The service sends a message to configure the launched development environment to execute a computer program written in the development environment using the computing cluster. The service generates a token to secure communications between the electronic device and the development environment and sends the token to an originator of the request.

Abstract: Disclosed herein are systems and methods for processing a gift request that use mobile computing devices to transfer a gift payment associated with the gift request. The mobile computing devices are capable of running a gift transfer application, which facilitates a transfer of the gift payment via a payment-processing server. A sender user execute the gift transfer application, using a mobile computing device, to transfer the gift payment, through a gift processing system that runs the gift transfer application, to a mobile computing device of a recipient user. One or more techniques authenticate the recipient user prior to processing the gift requests initiated by the sender user.

Abstract: The present invention provides methods of treating (including preventing) a disease or condition associated with abnormal angiogenesis in a subject include administering a therapeutically effective amount of an AA targeting compound of the invention to the subject. The AA targeting compounds comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody.

Abstract: The present invention provides various uses of VEGF binding peptides, including methods to treat disorders associated with abnormal angiogenesis. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules.

Abstract: The present invention relates to Multifunctional Antibody Conjugates, comprising an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CL?) comprising K188 according to Kabat numbering; a linker comprising the formula X-Y-Z, wherein Z is a group is covalently connected to the antibody through the side chain of K188, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety. The invention further provides specific MAC compounds and compositions of the invention.

Abstract: The present invention provides various uses of VEGF binding peptides, including methods to treat disorders associated with abnormal angiogenesis.

Abstract: The present invention provides VEGF binding peptides. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules. Various uses of the peptides and compounds are provided, including methods to treat disorders associated with abnormal angiogenesis.

Abstract: The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.

Abstract: The present invention relates to Multifunctional Antibody Conjugates, comprising an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CL?) comprising K188 according to Kabat numbering; a linker comprising the formula X-Y-Z, wherein Z is a group is covalently connected to the antibody through the side chain of K188, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety. The invention further provides specific MAC compounds and compositions of the invention.

Abstract: The present invention provides VEGF binding peptides. In addition, the invention provides VEGF peptides conjugated to antibodies alone and in conjunction with other anti-angiogenic molecules. Various uses of the peptides and compounds are provided, including methods to treat disorders associated with abnormal angiogenesis.

Abstract: An expanded business object model including one or more business objects including an inheritance property such that each business object includes a plurality of subtypes and roles for defining a functional aspect of the business object in a collaboration.

Abstract: A ultra-clean, ULSI-supportable process is described for cleaning and etching very thin layers of a semiconductor surface in a gaseous ambient at approximately room temperature. An oxidized surface is etched and cleaned in the vapors of azeotropic, aqueous acids. The cleaning properties of the vapors of the aqueous acids are such that metallic contaminants residing at the surface or within the oxidized layer are complexed and later rinsed away in a rinsing process. The surface is then re-oxidized in an ozone ambient, the resultant oxidation reaction being self-limiting such that the oxide layer is grown to a consistent, predetermined thickness. The process may be repeated any number of times depending on the depth at which any contaminants reside.